Forum Alert: Biosante Pharmaceuticals, Inc. Will Present at the Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum at The Princeton Club of New York on Wednesday, June 15, 2005, 1:25 pm ET

WILink Informed Investors Forum 2005
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--June 9, 2005--Biosante Pharmaceuticals, Inc. (AMEX: BPA) will present at the following forum:
What:  Informed Investors Biotechnology / Healthcare / Pharmaceutical 
       Investor Forum

When:     June 15, 2005 @ 1:25 PM Eastern Time

Sponsors:  Barron's, The Wall Street Journal, The American Stock 
           Exchange and Business Wire

Keynote Presentations:  Lynn Sutherland, M.S., M.B.A. - President, 
                        Sutherland Consulting Dr. Navdeep Jaikaria, 
                        Senior Biotechnology Analyst, Rodman &
                        Renshaw, LLC

Where:   The Princeton Club of New York, 15 West 43rd Street., New 
         York City, NY 10036

How to attend:  Pre-registration is necessary.  To register, contact 
Cary Loeser, cloeser@wilink.com, or 804-327-3407.   You may also call 
Customer Service at 888-301-6618, or register at the following link:
http://www.informedinvestors.com/CustomEvent/89559/index.asp

If you are unable to attend the live event, the forum will be 
available via webcast at
http://www.informedinvestors.com/CustomEvent/89559/index.asp

Contact: Phillip Donenberg, Chief Financial Officer, (847)478-0500, 
donenber@biosantepharma.com

BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(TM) (bioidentical testosterone gel) for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at www.biosantepharma.com.

Contacts

For Biosante Pharmaceuticals, Inc.:
Cary Loeser, Informed Investors, 804-327-3407
cloeser@wilink.com
http://www.informedinvestors.com

Better Be Business Wired.

Business Wire is the leading source for press releases, photos, multimedia and regulatory filings from companies and groups throughout the world.